1.25

0.79% -0.01

Pre-market: 1.25

Tempest Therapeutics Inc (TPST)

Overview News Price History Option Chain Financials Why TPST Down? Discussions Forecast Stock Split

Tempest Therapeutics Inc stock is traded at $1.25, with a volume of 70,645. It is down -0.79% in the last 24 hours and down -31.69% over the past month. Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.

Previous Close:

$1.26

Open:

$1.29

24h Volume:

70,645

Relative Volume:

0.37

Market Cap:

$18.51M

Revenue:

Net Income/Loss:

$-43.10M

P/E Ratio:

-0.2013

EPS:

-6.2098

Net Cash Flow:

$-26.38M

1W Performance:

-1.57%

1M Performance:

-31.69%

6M Performance:

-14.97%

1Y Performance:

-62.18%

1-Day Range:

$1.245

$1.30

1-Week Range:

$1.24

$1.305

52-Week Range:

$1.20

$6.115

Tempest Therapeutics Inc Stock (TPST) Company Profile

Name

Tempest Therapeutics Inc

Sector

Healthcare (1104)

Industry

Biotechnology (621)

Phone

415-798-8589

Address

2000 SIERRA POINT PARKWAY, BRISBANE

Employee

Twitter

Next Earnings Date

2026-05-12

Latest SEC Filings

TPST's Discussions on Twitter

Compare TPST vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TPST Tempest Therapeutics Inc	1.25	18.51M	0	-43.10M	-26.38M	-6.2098
VRTX Vertex Pharmaceuticals Inc	450.46	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.98	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	884.20	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	287.80	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	160.06	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-22-26	Upgrade	H.C. Wainwright	Neutral → Buy
Apr-10-25	Downgrade	H.C. Wainwright	Buy → Neutral
Apr-10-25	Downgrade	Scotiabank	Sector Outperform → Sector Perform
Mar-14-24	Initiated	Scotiabank	Sector Outperform
Feb-08-24	Initiated	Jefferies	Buy

Tempest Therapeutics Inc Stock (TPST) Latest News

Jun 09, 2026

Tempest Therapeutics (TPST) Edges Higher as Stock Tests Resistance Near $1.34EMA Signal - newsline.com

Jun 09, 2026

Jun 08, 2026

Director Richey William Drake reports 2,000 TPST shares on Form 3 - Stock Titan

Jun 08, 2026

Tempest Therapeutics (TPST) director awarded 25,000 stock options at $1.27 strike - Stock Titan

Jun 08, 2026

Warrant share approvals on ballot at Tempest Therapeutics (NASDAQ: TPST) - Stock Titan

Jun 08, 2026

Jun 04, 2026

Tempest Therapeutics Announces CFO Transition and Board Changes - TipRanks

Jun 04, 2026

Tempest Therapeutics appoints two directors to board - Investing.com UK

Jun 04, 2026

Tempest Therapeutics appoints two directors to board By Investing.com - Investing.com South Africa

Jun 04, 2026

Tempest Therapeutics (NASDAQ: TPST) CFO to depart while two independent directors join board - Stock Titan

Jun 04, 2026

Tempest Therapeutics, Inc. Announces Executive Changes, Effective June 5, 2026 - marketscreener.com

Jun 04, 2026

Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors - GlobeNewswire

Jun 04, 2026

Jun 03, 2026

Tempest Therapeutics Executes Warrant-Inducement Equity Financing Deal - The Globe and Mail

Jun 03, 2026

Jun 02, 2026

Tempest Therapeutics Raises $2.0M via Warrant Exercise, Issues New and Placement Agent Warrants - TradingView

Jun 02, 2026

Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds - 富途牛牛

Jun 02, 2026

Jun 01, 2026

TEMPEST THERAPEUTICS INC WT EXP Company Profile & Introduction - Moomoo

Jun 01, 2026

Tempest Therapeutics (TPST) inks $2M warrant exercise and new warrant deal - Stock Titan

Jun 01, 2026

May 31, 2026

Tempest Therapeutics, Inc. Files 8-K SEC Report Detailing Company Information and Stock Listing on NASDAQ - Minichart

May 31, 2026

May 29, 2026

Tempest Therapeutics Announces Resignation of Board Director - TipRanks

May 29, 2026

Tempest Therapeutics (TPST) asks shareholders to approve warrants convertible into millions of shares - Stock Titan

May 29, 2026

Tempest Therapeutics (TPST) director Simantov resigns and waives unpaid fees - Stock Titan

May 29, 2026

TPST Q1 2026 Earnings: Significant EPS Miss and No Revenue Reflect Pre-Revenue Stage PressuresNegative Surprise Momentum - The Legal Advocate

May 29, 2026

Tempest Therapeutics Q1 2026 Earnings: Wider-than-Expected Loss Amid Pre-Revenue Development StageEPS Surprise History - The Legal Advocate

May 29, 2026

Tempest Therapeutics secures $2M from warrant exercise By Investing.com - Investing.com Nigeria

May 29, 2026

Tempest Therapeutics secures $2M from warrant exercise - Investing.com

May 29, 2026

Tempest Therapeutics Announces Agreement for Warrant Exercise and New Short-Term Warrants - Quiver Quantitative

May 29, 2026

Tempest Therapeutics (TPST) Slumps 10%: Support Levels Under ScrutinyNegative Gamma - newsline.com

May 29, 2026

May 23, 2026